• Atea Pharmaceuticals expects existing cash and its initial credit facility draw to fund operations into mid-2028.
• Cash and investments totaled $191.2 million on Sept. 30, 2026; the initial draw was $65 million on Nov. 6.
• The Hercules Capital credit facility provides up to $200 million; additional funding and a successful BEM/RZR launch could bring Atea toward profitability.
• BEM/RZR peak annual US net sales could exceed $700 million, with pricing expected to align with existing branded direct-acting antiviral regimens.
• A US marketing application for BEM/RZR is targeted for mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.